Argent BioPharma Limited

ASX:RGT Stock Report

Market Cap: AU$18.8m

Argent BioPharma Management

Management criteria checks 4/4

Argent BioPharma's CEO is Roby Zomer, appointed in Feb 2016, has a tenure of 8.17 years. total yearly compensation is A$354.02K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.075% of the company’s shares, worth A$14.04K. The average tenure of the management team and the board of directors is 3.3 years and 3.3 years respectively.

Key information

Roby Zomer

Chief executive officer

AU$354.0k

Total compensation

CEO salary percentage100.0%
CEO tenure8.2yrs
CEO ownership0.07%
Management average tenure3.3yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Jun 23
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Mar 09
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

Oct 08
Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

Feb 21
If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

Dec 30
What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

CEO Compensation Analysis

How has Roby Zomer's remuneration changed compared to Argent BioPharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-AU$17m

Sep 30 2023n/an/a

-AU$19m

Jun 30 2023AU$354kAU$354k

-AU$21m

Mar 31 2023n/an/a

-AU$22m

Dec 31 2022n/an/a

-AU$23m

Sep 30 2022n/an/a

-AU$22m

Jun 30 2022AU$629kAU$422k

-AU$20m

Mar 31 2022n/an/a

-AU$19m

Dec 31 2021n/an/a

-AU$18m

Sep 30 2021n/an/a

-AU$17m

Jun 30 2021AU$481kAU$281k

-AU$16m

Dec 31 2020n/an/a

-AU$13m

Sep 30 2020n/an/a

-AU$16m

Jun 30 2020AU$440kAU$290k

-AU$19m

Dec 31 2019n/an/a

-AU$18m

Sep 30 2019n/an/a

-AU$14m

Jun 30 2019AU$495kAU$330k

-AU$11m

Dec 31 2018n/an/a

-AU$7m

Sep 30 2018n/an/a

-AU$7m

Jun 30 2018AU$498kAU$334k

-AU$8m

Mar 31 2018n/an/a

-AU$10m

Dec 31 2017n/an/a

-AU$12m

Sep 30 2017n/an/a

-AU$10m

Jun 30 2017AU$783kAU$233k

-AU$8m

Compensation vs Market: Roby's total compensation ($USD231.31K) is about average for companies of similar size in the Australian market ($USD295.26K).

Compensation vs Earnings: Roby's compensation has been consistent with company performance over the past year.

CEO

Roby Zomer (43 yo)

8.2yrs

Tenure

AU$354,018

Compensation

Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...

Leadership Team

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder8.2yrsAU$354.02k0.075%
A$ 14.0k
Tom Cairns
Chief Accounting Officer1.2yrsno datano data
Yifat Steuer
Deputy CEO & COO1.5yrsno data40.4%
A$ 7.6m
Nicole Godresse
Global Chief Sales Officer3.3yrsno datano data
Amir Polak
Chief Pharmaceutical Development Officerno datano datano data
Sabina Suljakovic
Head of the Quality Assurance Department3.6yrsno datano data
Nadya Lisovoder
Chief Medical Officerno datano datano data
Sasha Friedman
Deputy CEOno datano datano data
Yair Tal
Chief Information Security Officerno datano datano data
Robert Clements
Chief Commercial Officer1.8yrsno datano data
Itay Nissim
Chief Manufacturing & Supply Chain Officerno datano datano data
Hugh Winters
Chief Executive Officer of MGC Derma5.4yrsno datano data

3.3yrs

Average Tenure

Experienced Management: RGT's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roby Zomer
Co-Founder8.2yrsAU$354.02k0.075%
A$ 14.0k
Ross Grant Walker
Chairman of Strategic Advisory Boardno dataAU$44.00k0.011%
A$ 2.1k
Uri Kramer
Member of Strategic Advisory Board7.8yrsno datano data
Layton Mills
Independent Non-Executive Directorless than a yearno datano data
Wendyl D'Souza
Member of Medical Advisory Board5.8yrsno datano data
Daniel Robinson
Non-Executive Directorless than a yearno datano data
Shlomo Sadoun
Member of Advisory Boardno datano datano data

3.3yrs

Average Tenure

Experienced Board: RGT's board of directors are considered experienced (3.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.